# A Phase II Clinical Trial of Hydronidone Capsules(F351) in Patients With Liver Fibrosis Induced by HBV Chronic Hepatitis

> **NCT02499562** · PHASE2 · COMPLETED · sponsor: **Shanghai Genomics, Inc.** · enrollment: 168 (actual)

## Conditions studied

- Hepatitis B, Chronic

## Interventions

- **DRUG:** Hydronidone
- **DRUG:** Placebo
- **DRUG:** Entecavir

## Key facts

- **NCT ID:** NCT02499562
- **Lead sponsor:** Shanghai Genomics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06-25
- **Primary completion:** 2020-11-20
- **Final completion:** 2020-11-20
- **Target enrollment:** 168 (ACTUAL)
- **Last updated:** 2022-06-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02499562

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02499562, "A Phase II Clinical Trial of Hydronidone Capsules(F351) in Patients With Liver Fibrosis Induced by HBV Chronic Hepatitis". Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/clinical/NCT02499562. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*